Influenza Virus Research Reagents — HA, NA, NP, M2 Antibodies & Recombinant Proteins for Flu A & B

HA is the primary surface glycoprotein mediating receptor binding (sialic acid) and membrane fusion. HA is the principal immunogen in all influenza vaccines and the dominant target for neutralizing antibodies. abinScience provides the broadest HA subtype coverage available from a single supplier:

Biosimilar-Grade Reference Antibodies (Anti-HA)
Sequence-identical to clinical-stage anti-HA therapeutic antibodies for PK/ADA/bioactivity reference: Diridavumab (VK515016) (anti-H3), Firivumab (VK515026) (anti-Group 1 HA stem), Navivumab (VK515036), Gedivumab (VK515046) (anti-H1), and Lesofavumab (VK515056) (anti-Flu B HA).

Recombinant HA Proteins by Subtype
Full-length HA ectodomain or HA1 subunit proteins available in His/Fc tag formats for each subtype. Key subtypes with multiple strain variants:
• H1N1 — seasonal (A/California/2009, A/Michigan/2015) and pandemic strains
• H3N2 — seasonal (A/Hong Kong/2014, A/Kansas/2017)
• H5N1 — highly pathogenic avian influenza (HPAI)
• H7N9 — zoonotic avian influenza
• H2N2, H5N6, H5N8, H9N2, H10N3 — pandemic preparedness subtypes
• Influenza B — Victoria and Yamagata lineages
Browse the product list below for full strain-level detail and tag options.

Broadly Neutralizing Anti-HA Antibodies & Nanobodies
• HA stem-targeting broadly neutralizing antibodies (bnAbs): InVivoMAb VK515010 and format variants — these target the conserved HA stem region and neutralize across multiple Group 1 subtypes (H1, H2, H5, H6, H9)
• Anti-HA nanobodies: SD36 (VK515083), SD38 (VK515093), and additional clones for H1, H3, and H5 subtypes
• Subtype-specific anti-HA pAbs covering H1-H10 and Flu B

NA is the sialidase enzyme that cleaves sialic acid residues to release progeny virions from infected cells. NA is the target of oseltamivir (Tamiflu), zanamivir (Relenza), and peramivir (Rapivab). Anti-NA antibodies are increasingly recognized as an independent correlate of protection from influenza illness. abinScience provides NA recombinant proteins and polyclonal antibodies spanning all 11 NA subtypes (N1–N11), enabling comprehensive neuraminidase inhibition assays, surveillance serology, and drug resistance monitoring.

Key NA Products
• Recombinant NA proteins available for N1 through N11 — the broadest NA subtype panel from any single supplier
• Subtype-specific polyclonal antibodies for each NA subtype
• Recombinant anti-NA antibodies including CD6 (VK496013) and additional clones for NAI resistance profiling

Nucleoprotein (NP)
NP is the primary target for rapid influenza diagnostic tests (RIDTs) and the basis for Type A vs. Type B discrimination. NP is highly conserved within each type, making it ideal for broadly reactive diagnostics. Available: recombinant NP proteins for Flu A and Flu B, recombinant anti-NP antibodies (SAA0866 VK528013, SAA0867 VK528023), subtype-specific polyclonal antibodies, and monoclonal antibodies (1A256 VK714015, 1A257 VK714025).

Matrix Protein M2 / M2e Ectodomain
M2 is the proton-selective ion channel (amantadine target) and a leading universal influenza vaccine candidate — the M2e (ectodomain) is highly conserved across all IAV subtypes. Available: recombinant anti-M2/M2e antibodies 14C2 (VK736013), SAA1210 (VK736023), Fab60 (VK736033); recombinant M2 proteins; and M1/matrix proteins for multiple subtypes with paired polyclonal antibodies.

NS1 & Polymerase (PA)
NS1 is the major innate immune antagonist (IFN-β suppressor) and a virulence determinant — also a drug target for host-directed antiviral strategies. PA is a subunit of the heterotrimeric polymerase complex and the target of baloxavir marboxil (Xofluza). Available: PA recombinant protein N-His (VK560012), H1N1 PA protein (VK560022), and anti-PA pAb (VK560014).

Which HA subtypes do you cover?
Our HA protein panel covers H1, H2, H3, H5, H6, H7, H9, H10, and Influenza B (Victoria/Yamagata). Each subtype is available as recombinant HA ectodomain or HA1 in His/Fc tag formats. Multiple strain variants are offered for H1N1, H3N2, and H5N1 to support vaccine strain matching and antigenic cartography studies. Contact us for custom HA from specific outbreak or circulating strains.

Do you offer broadly neutralizing (bnAb) anti-HA antibodies?
Yes. Our HA stem-targeting InVivoMAb antibodies neutralize across Group 1 subtypes (H1, H2, H5, H6, H9) by blocking the pH-dependent conformational change required for membrane fusion. We also offer anti-HA nanobodies (SD36, SD38) that target conserved epitopes. These bnAbs are produced under low-endotoxin, azide-free conditions for in vivo studies.

How can I distinguish Flu A from Flu B in my assay?
Use NP (nucleoprotein) — it is the standard target for type discrimination. Our Flu A NP antibodies (SAA0866, 1A256) do not cross-react with Flu B NP, and vice versa. Pair with our type-specific NP recombinant proteins for sandwich ELISA or lateral flow development.

What are the biosimilar-grade reference antibodies used for?
Diridavumab, Firivumab, Navivumab, Gedivumab, and Lesofavumab are research-grade antibodies with sequences identical to clinical-stage anti-influenza therapeutics. They are used as positive controls, PK/ADA assay reference standards, and bioactivity benchmarks in influenza therapeutic antibody development programs.

Explore reagents for related respiratory viruses:

Influenza A & B ✓ RSV / HRSV hMPV SARS-CoV-2 Adenovirus Parainfluenza (PIV)